Invest now

Sun Pharma Advanced Research Company Ltd share price

High risk
  • 55%Low risk
  • 55%Moderate risk
  • 55%Balanced risk
  • 55%High risk
  • 55%Extreme risk
Analyse on
AI
  • ₹187.70(-2.11%)
    October 15, 2026 15:29:45 PM IST
    • NSE
    • BSE
  • Vol : 605.01 K (NSE + BSE)
    Last 20 day avg : 1.14 M
Sun Pharma Advanced Research Company Ltd is trading -2.11% lower at Rs 187.70 as compared to its last closing price. Sun Pharma Advanced Research Company Ltd has been trading in the price range of 193.40 & 187.50. Listed peers of Sun Pharma Advanced Research Company Ltd include Sun Pharmaceutical Industries (0.67%), Divi's Laboratories (0.11%), Torrent Pharmaceuticals (0.04%).The Mutual Fund holding in Sun Pharma Advanced Research Company Ltd was at 0.10% in 30 Sep 2026. The MF holding has increased from the last quarter. The FII holding in Sun Pharma Advanced Research Company Ltd was at 3.74% in 30 Sep 2026. The FII holding has decreased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Screen on
Try Now
Key Metrics

Updated on 16 Oct 2026, 02:41 AM IST

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.80
    High volatility
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
187.50
Highest
193.40
52 week range
Lowest
108.20
Highest
289.00
Sun Pharma Advanced Research Company Ltd Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries		1,760.600.674,22,416.9636.565.28--
Divi's Laboratories		9,039.950.112,39,982.2694.3114.76--
Torrent Pharmaceuticals		4,596.000.041,74,810.8175.8220.03--
Zydus Lifesciences		1,140.751.491,13,790.2520.744.15--
Cipla		1,333.701.591,07,744.0826.553.2--
Mutual Fund Ownership
View all
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 63.63
  • % of AUM 1.16
Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 5.76
  • % of AUM 0.24
Bandhan BSE Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.03
  • % of AUM 0.15
Mirae Asset Nifty Total Market Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.01
  • % of AUM 0.01
Bandhan Nifty Total Market Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.01
  • % of AUM 0.01
Sun Pharma Advanced Research Company Ltd Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-08-10Quarterly Results
2026-05-18Audited Results
2026-02-09Quarterly Results
2026-01-14To consider issue of Warrants & ESOP
2025-11-10Quarterly Results
About the company Sun Pharma Advanced Research Company Ltd
  • IndustryBiotechnology & Drugs
  • ISININE232I01014
  • BSE Code532872
  • NSE CodeSPARC
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company’s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.
  • Management Info
  • Anilkumar RaghavanChief Executive Officer
  • Anup RathiChief Financial Officer
  • Kajal DamaniaCompliance Officer, Company Secretary
Sun Pharma Advanced Research Company Ltd Share Price FAQs

Sun Pharma Advanced Research Company Ltd is trading at 187.70 as on Thu Oct 15 2026 09:59:45. This is -2.11% lower as compared to its previous closing price of 191.75.

The market capitalization of Sun Pharma Advanced Research Company Ltd is 6043.54 Cr as on Thu Oct 15 2026 09:59:45.

The 52 wk high for Sun Pharma Advanced Research Company Ltd is 289.00 whereas the 52 wk low is 108.20

Sun Pharma Advanced Research Company Ltd can be analyzed on the following key metrics -

  • TTM P/E:
  • Sector P/E: -
  • Dividend Yield: %
  • D/E ratio: -

Sun Pharma Advanced Research Company Ltd reported a net profit of - Cr in -.

The Mutual Fund Shareholding was 0.10% at the end of 30 Sep 2026.

Quick Links
EQUITY QUICK LINKS
Sun Pharma Advanced Research Company Ltd QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Sun Pharma Advanced Research Company Ltd share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.